Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co Ltd (TKPHF)
OTHER OTC:TKPHF
Total Valuation
Takeda Pharmaceutical Co has a market cap or net worth of $53.69B. The enterprise value is $12.48T.
Market Cap$53.69B
Enterprise Value$12.48T
Share Statistics
Takeda Pharmaceutical Co has 1,590,987,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,590,987,800
Owned by Insiders0.05%
Owned by Institutions<0.01%
Financial Efficiency
Takeda Pharmaceutical Co’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 3.14%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)3.14%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee92.97M
Profits Per Employee2.19M
Employee Count49,281
Asset Turnover0.32
Inventory Turnover1.75
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Co is 62.8. Takeda Pharmaceutical Co’s PEG ratio is -2.51.
PE Ratio62.8
PS Ratio1.52
PB Ratio1.00
Price to Fair Value1.00
Price to FCF9.15
Price to Operating Cash Flow7.38
PEG Ratio-2.51
Income Statement
In the last 12 months, Takeda Pharmaceutical Co had revenue of 4.58T and earned 107.93B in profits. Earnings per share was 68.36.
Revenue4.58T
Gross Profit2.46T
Operating Income627.54B
Pretax Income175.08B
Net Income107.93B
EBITDA1.13T
Earnings Per Share (EPS)68.36
Cash Flow
In the last 12 months, operating cash flow was 1.12T and capital expenditures -191.16B, giving a free cash flow of 931.22B billion.
Operating Cash Flow1.12T
Free Cash Flow931.22B
Free Cash Flow per Share585.31
Dividends & Yields
Takeda Pharmaceutical Co pays an annual dividend of $0.636, resulting in a dividend yield of 4.28%
Dividend Per Share$0.636
Dividend Yield4.28%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.26
52-Week Price Change22.03%
50-Day Moving Average30.13
200-Day Moving Average28.64
Relative Strength Index (RSI)51.26
Average Volume (3m)7.89K
Important Dates
Takeda Pharmaceutical Co upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateJan 28, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Takeda Pharmaceutical Co as a current ratio of 1.01, with Debt / Equity ratio of 63.50%
Current Ratio1.01
Quick Ratio0.52
Debt to Market Cap0.66
Net Debt to EBITDA4.31
Interest Coverage Ratio3.36
Taxes
In the past 12 months, Takeda Pharmaceutical Co has paid 66.94B in taxes.
Income Tax66.94B
Effective Tax Rate0.38
Enterprise Valuation
Takeda Pharmaceutical Co EV to EBITDA ratio is 10.49, with an EV/FCF ratio of 15.52.
EV to Sales2.58
EV to EBITDA10.49
EV to Free Cash Flow15.52
EV to Operating Cash Flow12.28
Balance Sheet
Takeda Pharmaceutical Co has $761.94B in cash and marketable securities with $4.85T in debt, giving a net cash position of -$4.09T billion.
Cash & Marketable Securities$761.94B
Total Debt$4.85T
Net Cash-$4.09T
Net Cash Per Share-$2.57K
Tangible Book Value Per Share-$1.28K
Margins
Gross margin is 56.31%, with operating margin of 13.70%, and net profit margin of 2.36%.
Gross Margin56.31%
Operating Margin13.70%
Pretax Margin3.82%
Net Profit Margin2.36%
EBITDA Margin24.61%
EBIT Margin7.99%
Analyst Forecast
The average price target for Takeda Pharmaceutical Co is $35.22, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$35.22
Price Target Upside9.14% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―